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Objective: Circulating free DNA (cfDNA) in general and circulating tumor DNA (ctDNA) in
particular is becoming an increasingly used form of liquid biopsy biomarkers. In this study,
we are investigating the ability to detect ctDNA from the plasma of pituitary adenoma
(PA) patients.
Design: Tumor tissue samples were obtained from planed PA resections, before which
blood plasma samples were taken. Somatic variants found in PA tissue samples were
evaluated in related cfDNA, isolated from plasma samples.
Methods: Sanger sequencing, as well as previously obtained whole-exome sequencing
data, were used to evaluate somatic variants composition in tumor tissue samples.
cfDNA was isolated from the same PA patients and competitive allele-specific TaqMan
PCR and amplicon-based next-generation sequencing (NGS) approach were used for
targeted detection of variants found in corresponding tumor tissue samples.
Results: Using NGS-based analysis, we detected five out of 17 somatic variants in
40 to 60% of total reads, three variants in 0.50–5.00% of total read count, including
GNAS c.601C>T, which was detected using ultra-deep NGS (1.78 million X) in 0.77%
of amplicons reads. Nine variants were not detected. We also detected We were not
able to detect variant found in PA tissue in cfDNA using cast-PCR, indicating that the
portion of variant-containing ctDNA in total isolated cfDNA is too small to be detected
with this method.
Conclusions: For the first time, we demonstrate the possibility to detect somatic
variants of PA in cfDNA isolated from patients’ blood plasma. Whether the source of
variant detected in cfDNA is PA should be further tested.
Keywords: pituitary adenoma, circulating tumor DNA, competitive allele-specific TaqMan, next-generation
sequencing, GNAS
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INTRODUCTION
Pituitary adenomas (PAs) are a group of diverse benign pituitary
tumors associated with increased morbidity and mortality
attributed to their hormonal hypersecretion, mass effects and
therapy-related adverse sequelae (1). Information about PAs’
prevalence varies between different studies and populations. For
example, the reported prevalence of symptomatic PAs varies from
3.9 cases per 100,000 people in western Sweden (2) to 77.6 cases
per 100,000 people in Banbury (Oxfordshire, UK) (1) or 115.6
cases per 100,000 people in Iceland (3). Several studies estimating
the PAs’ prevalence in general population disregarding their
clinical significance (using radiologic or post mortem studies)
have found that PAs are present in 10.4% (1) to 22.5% (4)
of people.
The pathogenesis of sporadic PAs remains unclear. These
adenomas have lower somatic variant rate thanmalignant tumors
and variants in classic oncogenes and tumor-suppressor genes are
relatively rare (5–7). Despite that, as mentioned by Caimari and
Korbonits (5) and supported by Song et al. (8), somatic variants
in specific genes, like, GNAS, USP8, or PIK3CA, can be found in
∼40% of sporadic PAs, and in some cases, knowing the status of
these somatic variants could be useful while choosing treatment
options (5, 8).
Due to the relatively high prevalence of PAs and the
inaccessibility of a tumor for tissue biopsies, it is useful to
evaluate the circulating biomarkers in blood for PAs’ diagnostics
and prognostics. Circulating free DNA (cfDNA) in general and
circulating tumor DNA (ctDNA) in particular is becoming a
more and more popular class of liquid biopsy biomarkers (9).
One of the biggest advantages of its uses as a biomarker is
that cfDNA can be extracted from blood plasma, which makes
sampling a minimally invasive procedure, compared to tissue
biopsies (10).
ctDNA has proven itself as a useful marker in several cancer
types. For instance, detection of estrogen receptor 1 (ESR1)
variants in ctDNA can be used for assessing possible response to
endocrine therapies or resistance to aromatase inhibitor therapy
in breast cancer (11). In the case of lung cancer, variants in
the epidermal growth factor receptor gene (EGFR) can be used
to predict the epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs) therapy effectivity (12). Whereas, in the
case of colorectal cancer, ctDNA quantity can be used to detect
tumor relapse in post-surgery surveillance months in advance
compared to conventional follow-up (13).
However, so far, there have been conflicting results regarding
the detection of ctDNA of benign neoplasms in blood plasma.
There are cases where ctDNA from aldosterone-producing
adenoma and benign colorectal adenomas reportedly have been
detected in patients’ plasma (14–16). However, other studies have
failed to detect ctDNA in patients with colorectal adenomas or
other neoplasms like thyroid nodules (17–19). Most of these
studies have evaluated differences in the total cfDNA quantity or
tried to detect tumor-specific variants in cfDNA using the PCR
basedmethods, which does not always have the highest sensitivity
comparing to next-generation sequencing (NGS) (20, 21). As
benign neoplasms have a potentially lower fraction of ctDNA
in plasma compared to cancers, methods that provide higher
sensitivity might be needed for comprehensive analysis in benign
tumors. Recently, it has been reported that even 0.3% variant
allele fractions of ctDNA can be detected by specifically designed
targeted NGS on Illumina NextSeq 500 (22).
The variants in the guanine nucleotide-binding protein,
alpha stimulating complex locus (GNAS) gene are frequently
encountered in PA tissue material studies. It is reported that
about 40% of somatotropinomas and with lower frequency also
other types of PAs have GNAS variants and these alterations
affect clinical characteristics of the disease (23–25). Therefore, the
ability to detect theGNAS variants in the blood of PA patients can
serve as a tool for the detection of prognostic markers.
No studies on the analysis of cfDNA in case of PA have been
published so far. This study is the first to investigate the ability
to detect ctDNA from the plasma of PA patients. Our strategy
includes the use of competitive allele-specific TaqMan PCR
(cast-PCR) and NGS for targeted detection of GNAS c.601C>T
variant. In addition, we employed NGS for a targeted search
of other adenoma specific variants identified from whole-exome
sequencing (WES) of germline—tumor DNA pairs from the
corresponding patients.
MATERIALS AND METHODS
Patients, Tissue, and Blood Samples
All samples and clinical information were obtained from patients
who underwent planned PA resections at Pauls Stradins Clinical
University Hospital and Riga East University Hospital. All
patients were recruited to the Genome Database of the Latvian
population (LGDB), a government-funded national biobank
(26). Two informed consents were obtained from each patient
after full explanation of the purpose and nature of all procedures
used, broad consent for LGDB for use of biological material
and medical data for human health and hereditary research,
and project-specific consent to the research of pituitary tumors.
Both biobank and PA research study have been approved by
the Central Medical Ethics Committee of Latvia (protocol No.
22.03.07/A7 and 01.29.1/28, respectively). Sample obtainment
and research process comply with the Declaration of Helsinki.
All patients (Table 1) had macroadenomas, eight of them
had confirmed extrasellar adenomas, but two patients had
endosellar adenomas. Three of them had clinical manifestations
characteristic to somatotropinomas and seven had clinical
manifestations characteristic to non-functioning pituitary
adenomas. According to IHC(P) analysis of PIT1, SF1, and
TPIT transcription profiles, HA074, HA090, and HA091 were
predominantly of PIT1 lineage, HA065, and HA067 were
predominantly of SF1 lineage, HA066 was predominantly of
TPIT lineage but HA068, HA069, HA070, and HA073 had
no data about expression of above-mentioned transcription
factors. Four of them were females, and six were males. Their
age distribution varied from 40 to 74 years. For eight patients
this was their first-time diagnosis of pituitary adenoma, but for
two patients this was relapse from previously operated PA. One
patient had somatostatin and dopamine analog therapy before
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TABLE 1 | Study sample description.






























HA065 6−69 NFPA SF1 Yes Primary No No variant NGS 272 3
HA066 50–59 NFPA TPIT Yes Primary No No variant NGS 671 2
HA067 70–79 NFPA SF1 Yes Relapse No No variant NGS 6 5
HA068 60–69 NFPA nd Yes Primary No No variant NGS 1 0
HA069 60–69 NFPA nd Yes Primary No No variant NGS and
cast-PCR
4 0
HA070 70–79 NFPA nd Yes Relapse No No variant NGS and
cast-PCR
12 4
HA073 50–59 NFPA nd Yes Primary No No variant NGS and
cast-PCR
10 2
HA074 40–49 GHPA PIT1 No Primary Yes GNAS
c.601C>T
cast-PCR 3 –





HA091 40-49 GHPA PIT1 Yes Primary No GNAS
c.601C>T
cast-PCR 5 –
sDNA, somatic DNA; cfDNA, circulating free DNA; WES, whole-exome sequencing; IHC(P), immunohistochemical analysis done on formalin-fixed paraffin-embedded samples; GHPA,
somatotropinoma; NFPA, non-functional pituitary adenoma; nd, no data, not performed.
resection, but the rest of the patients had no medicamentous
therapy before surgery.
Whole blood samples were collected in EDTA vacutainers
from patients before resection and in multiple cases 24 h after
resection as well. Plasma samples were obtained by centrifuging
whole blood for 10min, at 2,000 g, in room temperature. After
that, upper plasma layers were transferred to new 15ml tubes
and centrifuged for 10min, at 4,000 g, in room temperature in
order to remove remaining blood cells and prevent future cfDNA
contamination with germline DNA (gDNA). Obtained plasma
samples were aliquoted per 1ml and frozen in −80◦C for later
use within 2 h after whole blood sampling.
After resection, adenoma tissue samples were carefully
separated with a scalpel by the surgeon from any accompanying
tissue lesions or particles that have originated from adenoma
or neighboring tissue during surgery and adhered to the tumor
sample. The sample was submerged in RNAlater R© Solution
(Thermo Fisher Scientific, USA) for later nucleic acid extraction.
DNA Extraction
cfDNA was extracted from 2ml of plasma using QIAamp
Circulating Nucleic Acid Kit (Qiagen, Germany) following
the manufacturer’s instructions. Extraction outcome was
evaluated and cfDNA concentration measured using Agilent
High Sensitivity DNA kit and Bioanalyzer 2100 (Agilent
Technologies, USA).
gDNA was acquired from LGDB [details on the sample
preparation and DNA extraction are described by Rovite et al.
(26)]. Somatic DNA (sDNA) was extracted from tissue samples
using AllPrep DNA/RNAMini Kit (Qiagen, Germany), following
the manufacturer’s instructions. The concentration of extracted
gDNA and sDNAwas measured using QubitTM dsDNAHS Assay
Kit and Qubit 2.0 Fluorometer (Thermo Fisher Scientific, USA).
Sanger Sequencing and Cast-PCR
Sanger sequencing was applied to patients’ sDNA and
gDNA to estimate the presence of GNAS c.601C>T (NC_
000020.11:g.58909365C>T) and c.680A>T (NC_000020
.11:g.58909541A>T) variants. DNA was amplified using
GNAS_Fw, GNAS_Rs, GNAS227_Fw and GNAS227_Rs
primers (Supplementary Table 1) and sequenced using BigDye
chemistry and ABI PRISM 3130xl Genetic Analyzer (Thermo
Fisher Scientific, USA). All chromatograms were manually
inspected using Finch TV software (Geospiza Inc., USA).
Cast-PCR was performed on sDNA and cfDNA from selected
samples, using TaqMan R© Mutation Detection Mutant Allele
Assay GNAS_27887_mu /c.601C>T/ (Thermo Fisher Scientific,
USA) and ViiA7 Real-Time PCR System (Thermo Fisher
Scientific, USA). Twenty nanogram of sDNA samples were used
for the reaction, as recommended by the manufacturer. Since
cfDNA amount that could be extracted from blood plasma was
too low to meet the manufacturers’ recommendations for cast-
PCR reaction input, 2 µl of cfDNA samples were used for the
reaction, regardless of cfDNAs’ concentration. All reactions were
done in triplicates.
cfDNA Amplification and NGS
For this study, we used data from WES study (to be published
separately), analyzing DNA samples from peripheral blood
and pituitary tumor obtained from 10 PA patients. DNA
libraries were prepared with Illumina Nextera TruSeq Exome
kit (Illumina, USA) following manufacturer’s instructions and
sequencing was performed with Illumina NextSeq 500/550
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High Output v2 kit (150 cycles) (Illumina, USA). Paired-end
sequencing with read length 75 bp was carried out on Illumina
NexSeq 500 sequencer (Illumina, USA). Illumina exome target
manifest TruSeq Rapid Exome TargetedRegions v1.2 (Illumina,
USA) was used to define exome regions and Illumina Basespace
Enrichment App (v3.0.0) was used for data analysis. Variant
analysis revealed a median of 10 somatic variants per tumor. All
variants selected for this study were found in sDNA, but not in
gDNA, as well as they were validated with Sanger sequencing
(Supplementary Figure 2). Only those somatic variants that
were detected in sDNA of each individual patient were tested in
their corresponding cfDNA. Insertions and deletions were not
considered. Initially, we selected all validated variants with the
exception for HA065 and HA066, where due to the high number
of somatic variants three variants from each sample were selected.
In addition, variant in GNAS and VPS13D genes that have been
previously reported in relation to PA were included. This resulted
in total of 24 variants. We were able to obtain good quality PCR
fragments from cfDNA for 17 of these variants that were further
used in the study.
Primers (Supplementary Table 1) were designed according
to the variant positions found in whole-exome NGS using
Primer3plus (available at http://www.bioinformatics.nl/cgi-bin/
primer3plus/primer3plus.cgi). Primer sequences were checked
for unique human genome binding with UCSC In-Silico PCR
(available at http://rohsdb.cmb.usc.edu/GBshape/cgi-bin/hgPcr).
Amplicons were designed not to surpass the average length of
cfDNA fragment (165 bp).
Amplification of cfDNA regions, containing studied variants,
was done using HOT FIREPol R© (Solis BioDyne, Estonia). PCR
products were visualized in 1.2% agarose gel.
Due to different amplicon sizes (105, 111, and 119 bp),
they were divided into three libraries for cfDNAs’ NGS,
which were prepared with Ion Plus Fragment Library Kit
(Thermo Fisher Scientific, USA). Size selection and clean-up
between library preparation in all stages, except during end
repair, was performed with NucleoMag R© NGS Clean-up and
Size beads (Macherey-Nagel, Germany). Since NucleoMag R©
beads guaranteed size selection is between 150 and 800 bp,
during end repair stage NucleoMag R© beads were replaced
with SephadexTM G-50 Fine (GE Healthcare, USA) in order
to avoid excessive fragment loss as our fragments were
between 105 and 136 bp long. After ligation of barcode and
adapters, size selection was done with BluePippin Automated
DNA Size Selection System (Sage Science, USA) to decrease
the risk of contamination by adapter dimers. Quality and
quantity of prepared libraries were verified with High Sensitivity
DNA Reagents kit, High Sensitivity DNA Chips and Agilent
2100 Bioanalyzer (Agilent Technologies, USA). Preparation of
template-positive ion PITM Ion SphereTM Particles was done
on Ion OneTouchTM 2 instrument and Ion PITM Hi-QTM OT2
Solutions 200 kit (Thermo Fisher Scientific, USA). Prepared
libraries were sequenced using Ion PITM Hi-QTM Sequencing
200 Solution kit, Ion PITM Chip Kit V3 and Ion Proton System
(Thermo Fisher Scientific, USA). 7 pMol of each library were
used for sequencing, generating from 73,356 to 1,856,095 reads
per library.
Sequences from Ion Proton system were exported in fastq
format. Sequences were aligned to GRCh37—hg19 using BWA
(v 0.7.17-r1188) (27). Position statistics were calculated with
Samtools (v 0.1.19) (28). Alignments were reviewed with IGV
(v 2.3.14) (Broad Institute, USA) (29).
RESULTS
Sanger Sequencing and Cast-PCR
Both gDNA and sDNA obtained from 10 PA patients samples
were analyzed for the presence of GNAS c.601C>T and
c.680A>T somatic variants in tumor tissue by direct PCR
amplification of corresponding DNA fragment and subsequent
Sanger sequencing. The GNAS c.601C>T variant was present in
three tumor samples while none of the gDNA samples contained
this variant. None of the analyzed tumor tissue samples contained
GNAS c.680A>T somatic variant.
After determining the presence of tumor-specific c.601C>T
variant in tissue samples, we examined the ability of cast-PCR
to detect this variant in the cfDNA obtained from the plasma of
the corresponding patients. Amount of the cfDNA that we were
able to extract from 2ml blood plasma varied from 279.20 pg to
4.49 ng (13.96–224.40 pg/µl) (Supplementary Figure 1). None
of the samples met the manufacturer’s requirements for cfDNA
input amount for the cast-PCR (20 ng). Therefore, we used the
maximum amount (2 µl) of cfDNA per reaction, regardless of
its concentration. That constitutes a 44–716 times lower amount
of input DNA compared to the recommended one. sDNA from
variant-positive tissue samples were used as positive control
while sDNA from variant-negative tissue samples and related
cfDNAs were used as a negative control. As a result, we were able
to obtain a positive signal only from positive controls (Ct= 28.21
± 0.90). No signal was obtained from neither negative controls
nor cfDNA from GNAS c.601C>T positive samples, indicating
that the portion of GNAS c.601C>T variant-containing ctDNA
in total isolated cfDNA is too small to be detected with cast-PCR
or cfDNA does not contain ctDNA of PA origin.
NGS Based Analysis
For this study, we used WES data to identify cfDNA amplicon
targets. A number of identified somatic variants per patient, in
their sDNA but not gDNA, as well as the number of tumor
variants selected for this study, are shown in Table 1. Of the
24 somatic variants, 17 amplicons encompassing their location
were obtained from cfDNA while amplification of seven cfDNA
regions with somatic variants was not successful. All 17 obtained
amplicons were successfully sequenced withNGS. 82.35% of NGS
reads mapped to the target region with an average mapping
quality 57.0. The obtained depth of coverage at the variant sites
ranged from 444 X to 13,048 X (median 4,833 X).
In a result, eight out of 17 analyzed variants were convincingly
detected in cfDNA amplicons. Results of the cfDNA sequencing
can be divided into three categories with respect to the variant
frequency in the reads (Table 2). The first group includes five
variants in genes VPS13D, LDLRAD2, SPEN, GPATCH4, and
G6PC2 that were detected between 40 and 60% of the total reads
obtained from corresponding amplicons. Interestingly, all these
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TABLE 2 | Summary of NGS results.
Patient ID Gene Position of variant Wt/alt allele Total coverage Coverage
A C G T
Alternative allele content between 40.00 and 60.00% of the total reads
HA065 VPS13D chr1:12368563 C/T 10,585 6 5,420 11 5,148 (48.63%)
LDLRAD2 chr1:22150575 C/T 7,641 3 4,033 8 3,597 (47.07%)
SPEN chr1:16256795 A/G 444 225 0 218 (49.10%) 1
HA066 GPATCH4 chr1:156565233 C/T 8,726 9 3,611 1 5,105 (58.50%)
G6PC2 chr2:169764546 C/G 1,567 0 869 697 (44.48%) 1
Alternative allele content between 0.50 and 5.00% of the total reads
HA073 MPRIP chr17:17068722 C/T 3,066 0 2,949 5 112 (3.65%)
HA070 RYR1 chr19:38964226 G/A 882 20 (2.27%) 0 862 0
HA090 GNAS chr 20:58909365 C/T 1,744,103 76 1,730,527 118 13,382 (0.77%)
No alternative allele or at the same frequency as technological errors
HA067 CLCNKA chr1:16358671 C/G 1,666 0 1,664 0 2
SMARCAD1 chr4:95174031 A/G 8,968 8,958 2 8 0
PDE3A chr12:20774260 G/A 13,014 5 1 13,008 0
MTFMT chr15:65316064 A/T 5,964 5,950 0 13 1
PRPF8 chr17:1563731 A/G 8,239 8,227 0 12 0
HA070 CCDC138 chr2:109473249 G/A 4,833 4 0 4,829 0
FXR1 chr3:180633413 T/A 3,117 1 6 1 3,109
CLEC1B chr12:10149329 G/A 2,560 0 0 2,559 1
HA073 ATF4 chr22:39918305 C/A 1,336 0 0 1,336 0
wt, wild-type allele; alt, alternative allele. Bold indicates coverage of alternative alleles, italic indicates coverage of wild-type alleles.
five variants were identified in two individuals that also harbored
the highest number of total somatic variants (272 and 671) in
tumor tissue as identified by WES. The second group includes
three variants from three individuals in genes—MPRIP and RYR
(frequencies of 3.65 and 2.27%, respectively) who were identified
in sDNA, but not in gDNA in previously mentioned WES study,
and GNAS (0.77% frequency) who were identified in sDNA, but
not in gDNA in Sanger sequencing, mentioned in section Sanger
sequencing and cast-PCR (Supplementary Figure 2). The third
group includes identified somatic variants in genes CLEC1B,
ATF4, CLCNKA, SMARCAD1, PDE3A, MTFMT, CCDC138,
FXR1, and PRPF8 that were either not detected in any of the NGS
reads or detected in a small fraction of reads, ranging from 0.02to
0.15%. It should be noted that the substitution of the different
nucleotides can be found across all positions examined or any
other position of the alignment that corresponds to the rate of
the technical error of the used sequencing platform which at this
study were 0.22%.
DISCUSSION
During recent years, liquid biopsies and cfDNA has been studied
in relation to different tumors and other diseases (30, 31). Despite
the theoretically high prevalence of PAs and the broad effect on
the organism caused by these tumors (32, 33), there are no studies
that would examine the usability of ctDNA in PA diagnostics and
prognostics. In our knowledge, this is the first study that attempts
to detect ctDNA of PA origin in the patient’s bloodstream.
cfDNA has been mostly studied as a prognostic tumor marker
in malignant tumor types. It is widely reported that cfDNA
amount in patients’ bloodstream is significantly higher in cancer
patients than a healthy subject, with higher amounts indicated in
latter tumor stages compared to early (34–36). In other studies,
researchers have applied WES to cfDNA and matching tumor
samples, and they had found that cfDNA represents the genomic
characteristics of a tumor (37, 38). In benign tumors, ctDNA
detection has proven to be more challenging as in some cases this
has been successful (14–16), but in others not (17–19).
Apoptosis, necrosis and possibly active secretion have been
thought to be the main mechanisms of cfDNA release in the
blood (39). However, a recent study has highlighted a stronger
correlation of ctDNA detection with cellular proliferation than
with cell death (40). It can be further theoreticized, that in the
case of fast-growing cancers, rapid cell proliferation could result
in relatively higher amounts of ctDNA released in the blood,
which can be further isolated and analyzed. However, since the
benign tumors generally have slower growth and consequently
the proliferation rate, ctDNA could be released in lower amounts,
resulting in a lower concentration in blood. For this reason,
in case of the benign tumors, ctDNA could be much harder
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to detect and analyse. On the other hand, many pituitary cells
being secretory by nature may contribute to the appearance of
cfDNA from these cells into plasma. So far, several attempts
have been published to analyse variants in ctDNA from benign
tumors of different origin. Lupo et al. measured ctDNA yield in
blood plasma from patients with thyroid nodules and analyzed
variant content, using commercial assay and NGS. Although they
managed to detect ctDNA in two patients, authors concluded that
neither cfDNAmeasurements nor ctDNA variants detectionwere
sensitive or specific enough to be used in clinical practice instead
of analysis of tissue biopsy (19).
In our first attempt to analyse ctDNA from PAs, we have
chosen well-known recurring somatic variant (c.601C>T) in the
GNAS gene and succeeded to identify three tumors from PA
patients with this variant. We used cast-PCR and allele-specific
TaqMan assay to detect this variant in the cfDNA obtained from
the plasma of the corresponding patients. Although cast-PCR is
reported to have 0.10–1.00% variant detection limit in cfDNA
(21), we were not able to find the presence of c.601C>T variant
in any of these samples. Cast-PCR sensitivity can be affected by
the fact, that amount of cfDNA input that we used was lower than
manufacturer’s recommended, due to a limited amount of cfDNA
that we were able to extract from blood plasma. It is, of course,
plausible that the amount of ctDNA that comes from PA in the
bloodstream could be too low to be detected with this method
because PAs are generally slow-growing benign tumors.
The method described above, however, has significant
limitations. First, only patients with specific GNAS variant are
investigated. Secondly, also the number of genomic sites per
tumor/patient is limited to one. We, therefore, used NGS based
sequencing of amplicons fromWES determined genomic regions
to estimate and quantify the possible presence of ctDNA in eight
patients. This approach requires the prior knowledge of patient
specific somatic variants found in tumor tissue. In our case, we
selected variants identified in WES and Sanger sequencing study
analyzing gDNA obtained from peripheral blood cells and sDNA
from a pituitary tumor obtained from the same PA patients. In
total 17 somatic variants, that were found in sDNA, but not in
gDNA, were analyzed in six patients from corresponding cfDNA
amplicons. From all analyzed variants the GNAS gene variant
has been reported in several other studies, as mentioned above
(7, 23–25). Notably, two genes VPS13D and RYR1 have also been
reported to contain somatic variants in GH secreting PA tissue
(41), but the localization of the variants was different than we
found in our study. Further investigation is needed to explore the
potential functional role of these genes in PA development.
In three patients majority of somatic variants were not
detectable at the convincing level and only three variants were
detected between 0.5 and 5.0% of the total reads that in general
corresponds to the levels of a tumor-specific DNA found in the
cfDNA shown in the studies exploring different cancers. One
of these variants was c.601C>T that could not be identified
with cast-PCR and allele-specific TaqMan assay. From these
results, we conclude that the concentration of ctDNA in case
of PAs are at the boundary of detection with semiconductor
sequencing technologies and below the boundary for detection
with cast-PCR and TaqMan technologies. Although the results
of this study indicate successful detection of the variants in
plasma-derived cfDNA in some cases, the read count obtained
from the sequencing is on the borderline of sensitivity and cannot
be used for tumor variant monitoring in a clinical setting with the
presented technology. Potentially, other molecular techniques,
for example, digital droplet PCR could be further studied to
develop more sensitive monitoring methods.
The results obtained from two patients included in the study
are unexpected. First of all, tumors from these patients are
characterized with a higher number of somatic variants (272
and 671) than usually observed in benign PAs, but no clinical
manifestations indicating increased aggressiveness or recurrent
pathological tumors were identified in these patients. All five
variants from these patients that we were able to detect had
between 40 and 60% of the total reads that is unusually high
for a ctDNA. One can hypothesize that high amount of genetic
changes in these tumors could contribute to mechanisms that are
related with ctDNA release into the bloodstream or these variants
could be present in other tissues in patients bodies with high
activity of mechanisms that promote cfDNA release.
In summary, for the first time, we demonstrate the possibility
to detect somatic variants of PA in cfDNA isolated from patients’
blood plasma. Beside others, we were able to detect variant in the
GNAS gene, whose impact on PA has been widely described in the
literature. Whether the source of variant detected in cfDNA is PA
should be further tested.
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Supplementary Figure 1 | Size and concentration of two representative cfDNA
samples that have been extracted from 2ml of PA patients’ blood plasma and
eluted in 20 µl. Measurement was done using Agilent High Sensitivity DNA kit and
Bioanalyzer 2100 (Agilent Technologies, USA). (1) indicates cfDNA sample, (2)
indicates High Sensitivity DNA ladder lower marker, (4) indicates High Sensitivity
DNA ladder upper marker. In both samples, cfDNA size was around 170 bp, but
concentration warried from 13.96 to 224.40 pg/µl.
Supplementary Figure 2 | Validation of LDLRAD2, SPEN, VPS13D, G6PC2,
GPATCH4, CLCNKA, MTFMT, PDE3A, PRPF8, SMARCAD1, CCDC138,
CLEC1B, FXR1, RYR1, ATF4, MPRIP gene variants with Sanger sequencing in
pituitary adenoma somatic (PA) DNA and patients germline DNA from samples
HA065, HA066, HA067, HA070, HA073, and HA090.
Supplementary Table 1 | Used primers (Metabion international AG, Germany).
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